Posted by Michael Wonder on 14 Jul 2020
Gilead rushes to meet remdesivir demand as virus pressures grow
15 July 2020 - Global pharmaceuticals giant Gilead has flagged the supply of its coronavirus treatment remdesivir will be constrained until September, though the local arm of the business has said it is focused on extending the drug to more patients as well as ensuring Australia is prepared for future pandemics.
Last week the Therapeutic Goods Administration granted provisional approval for use of Gilead's Remdesivir, which trades as Veklury, in Australia.
It is the first coronavirus treatment option to be approved for use in hospitalised patients.
